Microba Life Sciences becomes the first Australian microbiome company to achieve ISO15189 accreditation from NATA

Brisbane, Australia – (COMMERCIAL THREAD) – Microba has applied its cutting edge technology for microbiome analysis to unlock diagnostic applications, receiving ISO15189 accreditation for a new non-targeted test based on NGS of stool samples.

The Hypothesis-Free Test Method, MetaPanelMT, can identify multiple pathogens simultaneously from a single sample and has been developed in partnership with Australian hospitals and leading healthcare professionals.

Microba’s advanced bioinformatics analysis and laboratory processing pipelines at the Translational Research Institute in Brisbane have received ISO15189 accreditation to enable the use of MetaPanelMT, in clinical settings for impartial detection of causative agents of gastrointestinal infectious diseases.

As an international standard for medical laboratories, ISO15189 accreditation guarantees the validity and reliability of testing services for patient samples and involves independent evaluation of the laboratory’s pre-analytical, analytical and post-analytical processes. In Australia, the accreditation program is delivered by the NATA (The National Association of Testing Authorities, Australia) in collaboration with the Royal College of Pathologists of Australasia (RCPA).

Associate Professor Paul Griffin, director of infectious diseases at Mater Hospital, explained that he expects significant growth in the use of this type of diagnostic test given the better understanding of advanced sequencing technologies. .

“The application of metagenomic analysis to stool samples for the detection of pathogens opens up the possibility of improving patient outcomes by improving our ability to detect, understand and follow infectious diseases in a clinical setting”, said Assistant Professor Paul Griffin.

Through validation studies conducted on more than 2,500 samples, the performance of non-target tests has been correlated with traditional diagnostic methods, in a shorter time frame with comparable or improved sensitivity and improved specificity.

Dr Nicola Angel, Laboratory Director at Microba, said obtaining this accreditation is another important step to ensure rigor at every step of Microba’s analysis and ensure that partners can be confident in their results.

“We see a future where microbiome testing will become a part of routine clinical care to improve patient outcomes. Therefore, ensuring that our laboratory and processes meet standards for valid and reliable test results has been central to our approach to microbiome analysis, ”she added. .

Microba’s DNA extraction, sequencing, secondary and tertiary (bioinformatics) analyzes are also included in the scope of ISO15189 accreditation.

Following this accreditation, the accuracy of Microba’s bioinformatics tools has been published in Frontiers in microbiology and its sampling device calibrated in ISME Communications.

Partners wishing to access Microba’s cutting-edge microbiome analysis can contact Microba directly.

About Microba Life Sciences

Microba Life Sciences is a precision microbiome science company with a mission to improve human health. With cutting-edge technology for microbiome analysis, Microba is developing new treatments and innovative test solutions that harness the microbiome for better health outcomes. Microba partners with leading organizations globally to drive microbiome discovery and advance new applications for the role of the microbiome in human health. To learn more, visit www.microba.com.

Comments are closed.